Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00397488 | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00588666 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 |
| clinicaltrials |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2016 | clinicaltrials |
| NCT00234039 | S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin | completed | Phase 2 | 58 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00618982 | Sorafenib Dose Escalation in Renal Cell Carcinoma | completed | Phase 2 | 83 | BayerINDUSTRY | 5 | Dec 24, 2015 | clinicaltrials |
| NCT00480389 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | completed | Phase 2 | 19 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00585689 | Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00459875 | Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT01824329 | Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer(SPARC) | completed | Phase 2 | 40 | University of MichiganOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02002312 | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer | completed | Phase 2 | 14 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00556621 | Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer(GEMCIRAV) | completed | Phase 1 / Phase 2 | 14 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00047216 | Tipifarnib in Treating Patients With Recurrent Bladder Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00066352 | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00609934 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
| NCT00126490 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00854620 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)(Bladder Cancer) | completed | Phase 2 / Phase 3 | 90 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02030717 | Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma(ASA) | completed | Phase 2 / Phase 3 | 120 | Umeå UniversityOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00083109 | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00731211 | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT00019955 | Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer) | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00422019 | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 61 | AmgenINDUSTRY | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02006667 | A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00136175 | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00126503 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00661375 | BAY43-9006 Phase II Study for Renal Cell Carcinoma | completed | Phase 2 | 131 | BayerINDUSTRY | 1 | Dec 25, 2014 | clinicaltrials |
| NCT01034878 | Sunitinib in Metastatic Renal Cancer | completed | Phase 2 | 25 | Istituto Clinico HumanitasOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00455975 | High-dose Bevacizumab in Advanced Renal Carcinoma Patients | completed | Phase 2 | 119 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00044564 | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 54 | BayerINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | completed | Phase 2 | 501 | BayerINDUSTRY | 2 | Dec 19, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00520403 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | completed | Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00570882 | Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 76 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00866320 | Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab | completed | Phase 2 | 49 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01408004 | Rotating Pazopanib and Everolimus to Avoid Resistance(ROPETAR) | completed | Phase 2 | 101 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00265135 | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 68 | Centocor, Inc.INDUSTRY | 4 | Jul 3, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2016source: clinicaltrials